Annual cashflow statement for Sagimet Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -24.4 | -30.5 | -27.9 | -45.6 | -51 |
| Non-Cash Items | 2.79 | 1.79 | 5.09 | 4.18 | 6.44 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.055 | 4.21 | -0.978 | -1.05 | -1.05 |
| Change in Prepaid Expenses | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -21.7 | -24.5 | -23.8 | -42.4 | -45.6 |
| Other Investing Cash Flow Items | 0 | -32 | 12.6 | -61.7 | 4.56 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 0 | -32 | 12.6 | -61.7 | 4.56 |
| Financing Cash Flow Items | -1.25 | -0.085 | 86.2 | -1.04 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 9.74 | -0.073 | 86.2 | 105 | 0.275 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -12 | -56.6 | 75 | 0.701 | -40.8 |